Indian Biotech Breakthroughs

India's biotech story in 2025-26 is really four separate firsts at very different stages of ripeness, and the exam-smart move is to know exactly how far each has actually travelled. NexCAR19, a made-in-India cancer therapy, is already treating patients. BIRSA 101, an indigenous CRISPR fix for sickle cell disease, has just been unveiled and handed to industry to develop. AdFalciVax, a home-grown malaria vaccine, is still an early candidate. And at Kashmir's agricultural university, scientists have produced the country's first gene-edited sheep. One card, four maturity levels.